Case Report: Hypereosinophilic Syndrome Response to Infliximab in a Patient with Ulcerative Colitis

Abstract

Introduction: We present a case of a caucasian 83-year-old female with a previous diagnosis of ulcerative colitis (UC) admitted to our institution with a mild UC flare and a hypereosinophilic overlap syndrome refractory to corticosteroids but that responded to intravenous infliximab.

Conclusion: Hypereosinophilic Syndrome (HES) is a very rare disorder that usually appears in people between 20 to 50 years old although it can also occur in elderly people and children. It affects equally to both sexes and several mechanisms have been proposed related to the excess in the synthesis of eosinophils. The clinical course may be silent or present different manifestations depending on the affected tissue. The diagnostic workup should include blood tests, imaging tests and tissue biopsies. A bone marrow aspiration and biopsy are necessary if all the previous studies are normal. Early diagnosis and treatment of HES have a significant impact on survival. Treatment of asymptomatic patients is based on close monitoring to prevent complications. In symptomatic cases, empiric corticosteroids or other immunosuppressive agents should be used. Hematopoietic cell transplantation is the last therapeutic alternative.

Keywords: Hypereosinophilic Syndrome (HES); Ulcerative Colitis; Infliximab; hypereosinophilia

Introduction

There are many conditions associated with plasma and tissue eosinophilia (Table 1). The degree of eosinophilia can be mild (500-1500 Eos/µL), moderate (1500-5000 Eos/µL) or severe (>5000 Eos/µL). Hypereosinophilic Syndrome (HES) is defined as either hypereosinophilia over 1500 eosinophils/µL in at least 2 determinations or as tissue damage secondary to eosinophilic infiltration [1,2]. The present case report is a patient with a previous diagnosis of ulcerative colitis (UC) admitted to our institution with a suspected mild UC flare and a hypereosinophilic overlap syndrome refractory to corticosteroids but who responded to infliximab.

Table 1: Pathologies associated with eosinophilia.

<table>
<thead>
<tr>
<th>Eosinophilia</th>
<th>Allergies</th>
<th>Infections</th>
<th>Lymphoproliferative disorders</th>
<th>Neoplasms</th>
<th>Organ specific diseases</th>
<th>Immunological</th>
<th>Endocrine</th>
</tr>
</thead>
</table>

Case Report

A caucasian 83-year-old female with no drug allergies and with a previous history of extensive UC diagnosed 2 years before being admitted to our hospital on September 8th 2013 due to bloody diarrhea, with 18-20 passes per day during the last month. She also complained of abdominal pain, hyporexia and weight loss. She was hemodynamically stable, with mild signs of dehydration. Physical examination showed diffuse abdominal pain but no signs of peritoneal irritation and peristalsis was preserved. She presented edema with fovea in both lower limbs extended to both knees. Digital rectal examination did not reveal masses.

Laboratory tests showed inflammatory activity with erythrocyte sedimentation rate (ESR) 50 mm, C reactive protein (CRP) 2.52 mg/dL, 28500 leukocytes/mm³ (neutrophils 17000/mm³, eosinophils 8900/mm³), 445000/mm³ platelets, hemoglobin 12.3 g/dL, blood iron 19 µg/dL, albumin 1.8 g/d. According to Truelove criteria, the patient has a severe flare up (21 points). She had an abdominal RX done which showed nothing relevant and she was started on intravenous corticosteroids and antibiotics (ciprofloxacin plus metronidazole), oral nutritional and iron supplementation. A colonoscopy was performed and revealed a severe ulcerative colitis. No histological or immunohistochemical signs of super infection by cytomegalovirus (CMV) were observed. Stool cultures and parasites in stool were both negative.

Clinical evolution was good and the patient was discharged from hospital with oral medication and ambulatory monitoring. Two weeks later, on September 26th, the patient was again admitted with a mild UC flare. Laboratory tests showed thrombocytopenia (77000 mil/mm³) and an increased leucocyte (36,300 per mm³) and eosinophil (19,700 per mm³) count. Eosinophilia was present 5 months before the flare (since May 2013), before corticoid
Ulcerative Colitis. Gastroenterol Hepatol Open Access 5(5): 00158. DOI:

Citation:

Chiari syndrome. The diagnostic workup should include blood 

tests including liver enzymes, creatine kinase, troponins and renal 
function, electrocardiogram, echocardiogram, chest radiography, 
chest and abdominal CT, and tissue biopsies. Several biomarkers 
are currently under study and could be useful as predictors of 
different subtypes of HES. Serum tryptase, vitamin B12 and 
serum IgE have to be analyzed. A bone marrow aspiration and 
biopsy with immunohistochemical and molecular techniques (1,5) 
are necessary if all the previous studies are normal.

Treatment of asymptomatic patients is based on close 
monitoring to prevent complications. In symptomatic cases, 
empiric corticosteroids should be started (which are the first 
option in lymphoid variants). Other drugs such as Imatinib (for 
PDGFRA or PDGFRB variants), hydroxyurea or leukapheresis 
are used in refractory cases to steroids. Treatment with alpha 
interferon, mepolizumab (anti-IL5), alemtuzumab (anti-CD52) and 
other chemotherapeutic agents such as cladribine, chlorambucil, 
vincristine, methotrexate, cyclosporine and etoposide have been 
evaluated in specific cases. Hematopoietic cell transplantation 
should be considered as the last therapeutic alternative when 
everything else has failed [1-10]. Anti-TNF administration has 
been reported to induce severe eosinophilic gastroenteritis in a 
patient with Crohn’s Disease [11]. However, we believe, according 
to our experience that infliximab administration is safe in such 
patients, and that eosinophilic gastroenteritis is more probably to 
be secondary to the disease instead of the medication.

Conclusion

In conclusion, the overlap between HES and other conditions, 
such us in our patient UC, may response to the treatment of the 
underlying disease [12]. Infliximab can be a good therapeutic 
alternative, when conventional medical treatment fails. Early 
diagnosis and treatment of HES have a significant impact on 
survival that increases from 12% at 3 years in cases of delayed 
diagnosis to 80% at 5 years in the case of early diagnosis [1].

Consent Statement

Written informed consent was obtained from the patient for 
publication of this case report and any accompanying images.

Authors Contribution Section

MS and PL were in charged of the patient and drafted the 
manuscript. FG participated in the design of the case report. AF 
coordinated and helped to draft the manuscript. AL supervised the 
manuscript once it was finished. All authors read and approved 
the final manuscript.

References

disorders: 2014 update on diagnosis, risk stratification and 
management. AJH 89(3): 325-337.
(2010) Refining the definition of hypereosinophilic syndrome. J 
Allergy Clin Immunol 126(1): 45-49.
Pathogenesis and classification of eosinophil disorders: a review of 

Copyright: ©2016 Marina et al.


